Medical device stocks rise in relief after Wegovy heart benefits data

To be sure, the full results presented on Saturday at a major medical meeting gave analysts even more confidence in the heart protective benefits of the hugely popular drug. "We believe key findings could be seen as a marginal positive for some, but not all, verticals within MedTech, especially given currently depressed sentiment," said Baird analyst Jeff Johnson. Its shares have tumbled about 28% as of last close since Novo in August said Wegovy had also shown a clear cardiovascular benefit.

Related Keywords

Bengaluru , Karnataka , India , Mike Kratky , Eli Lilly Mounjaro , Sriraj Kalluvila , Jeff Johnson , Leroy Leo , Medha Singh , Abbott Laboratories , Medtronic , Novo Nordisk , Reuters , Eli Lilly ,